Safety and Efficacy of Responsive Neurostimulation in Pediatric Epilepsy—a Single Center Experience
Abstract number :
2.055
Submission category :
3. Neurophysiology / 3E. Brain Stimulation
Year :
2023
Submission ID :
463
Source :
www.aesnet.org
Presentation date :
12/3/2023 12:00:00 AM
Published date :
Authors :
Presenting Author: Steven Lee, MD, PhD – Baylor College of Medicine, Texas Children's Hospital
Shital Patel, MD – Duke University; Cemal Karakas, MD – University of Louisville; Kimberly Houck, MD – Baylor College of Medicine, Texas Children's Hospital; Cristina Trandafir, MD – Baylor College of Medicine, Texas Children's Hospital; James Riviello, MD – Baylor College of Medicine, Texas Children's Hospital; Howard Weiner, MD – Baylor College of Medicine, Texas Children's Hospital; Daniel Curry, MD – Baylor College of Medicine, Texas Children's Hospital; Irfan Ali, MD – Baylor College of Medicine, Texas Children's Hospital
Rationale:
Responsive neurostimulatoin (RNS) is an effective long-term FDA-approved treatment for adults with focal drug-resistant epilepsy (DRE) and—particularly when the EZ involves eloquent cortex or when surgery is not an option. RNS has been used off-label in children and is undergoing a safety and efficacy study in patients 12-18 years old. Current available data on the safety and efficacy of RNS in children is limited. Here we report our center’s experience with RNS.
Methods:
A retrospective chart review was performed on patients with RNS implanted or managed at Texas Children's Hospital (TCH) between July 2016 to March 2023 (n=66). Clinical data were reviewed according to an institutional review board-approved protocol. For baseline and demographic data (n=65), we excluded one patient who had the RNS implanted due to refractory electrical status epilepticus of sleep. For outcome data (n=49), we included patients with at least nine months of follow-up. Patients excluded from seizure outcomes were: six followed at other institutions, nine with <
Neurophysiology